Compare Stocks: CMPS, LNTH, AMRX, and BLTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$20.30 -0.2%	$18.39	$9.56 ▼ $21.17	$6.50B	1.22	3.04 million shs	3.59 million shs
BLTE Belite Bio	$155.61 -2.2%	$166.49	$76.23 ▼ $200.00	$6.41B	-1.23	182,160 shs	190,256 shs
CMPS Compass Pathways	$11.56 -0.3%	$13.42	$4.88 ▼ $15.87	$1.61B	2.55	3.19 million shs	2.79 million shs
LNTH Lantheus	$99.95 -0.2%	$100.50	$49.67 ▼ $111.86	$6.54B	-0.06	1.00 million shs	730,105 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	-0.25%	+0.50%	+16.40%	+19.69%	+92.42%
BLTE Belite Bio	-2.24%	-6.63%	-19.63%	+2.17%	+99.24%
CMPS Compass Pathways	-0.34%	-10.80%	-12.89%	-17.25%	+83.78%
LNTH Lantheus	-0.24%	+0.44%	-1.01%	-6.37%	+89.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$20.30 -0.2%	$18.39	$9.56 ▼ $21.17	$6.50B	1.22	3.04 million shs	3.59 million shs
BLTE Belite Bio	$155.61 -2.2%	$166.49	$76.23 ▼ $200.00	$6.41B	-1.23	182,160 shs	190,256 shs
CMPS Compass Pathways	$11.56 -0.3%	$13.42	$4.88 ▼ $15.87	$1.61B	2.55	3.19 million shs	2.79 million shs
LNTH Lantheus	$99.95 -0.2%	$100.50	$49.67 ▼ $111.86	$6.54B	-0.06	1.00 million shs	730,105 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	-0.25%	+0.50%	+16.40%	+19.69%	+92.42%
BLTE Belite Bio	-2.24%	-6.63%	-19.63%	+2.17%	+99.24%
CMPS Compass Pathways	-0.34%	-10.80%	-12.89%	-17.25%	+83.78%
LNTH Lantheus	-0.24%	+0.44%	-1.01%	-6.37%	+89.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	2.90	Moderate Buy	$21.00	3.45% Upside
BLTE Belite Bio	2.64	Moderate Buy	$218.73	40.56% Upside
CMPS Compass Pathways	2.88	Moderate Buy	$23.36	102.05% Upside
LNTH Lantheus	2.29	Hold	$108.11	8.17% Upside

Current Analyst Ratings Breakdown

Latest CMPS, LNTH, AMRX, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	BLTE Belite Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/1/2026	AMRX Amneal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/25/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/23/2026	AMRX Amneal Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
9/17/2026	AMRX Amneal Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $20.00
9/10/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/9/2026	CMPS Compass Pathways	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/9/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$220.00 ➝ $234.00
9/9/2026	BLTE Belite Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
9/9/2026	AMRX Amneal Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
9/9/2026	AMRX Amneal Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00

(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.02B	2.15	$1.56 per share	13.03	($0.23) per share	-88.26
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
CMPS Compass Pathways	N/A	N/A	N/A	N/A	($0.55) per share	N/A
LNTH Lantheus	$1.54B	4.23	$6.37 per share	15.69	$16.43 per share	6.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	41.43	18.80	2.39	5.05%	-584.46%	7.78%	N/A
BLTE Belite Bio	-$77.61M	-$2.73	N/A	171.00	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
CMPS Compass Pathways	-$287.86M	-$4.62	N/A	N/A	N/A	N/A	-49.63%	-13.08%	11/3/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.14	17.82	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)

Latest CMPS, LNTH, AMRX, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	CMPS Compass Pathways	-$0.3629	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/5/2026	Q2 2026	CMPS Compass Pathways	-$0.3881	-$1.88	-$1.4919	-$1.88	N/A	N/A
7/30/2026	Q2 2026	AMRX Amneal Pharmaceuticals	$0.24	$0.30	+$0.06	$0.18	N/A	$796.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CMPS Compass Pathways	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
BLTE Belite Bio	N/A	33.56	33.56
CMPS Compass Pathways	0.60	1.30	1.30
LNTH Lantheus	0.43	3.06	2.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
BLTE Belite Bio	0.53%
CMPS Compass Pathways	46.19%
LNTH Lantheus	99.06%

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
BLTE Belite Bio	13.29%
CMPS Compass Pathways	2.82%
LNTH Lantheus	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
BLTE Belite Bio	41	40.27 million	34.92 million	Not Optionable
CMPS Compass Pathways	156	138.48 million	134.57 million	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable

CMPS, LNTH, AMRX, and BLTE Headlines

Recent News About These Companies

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Option Care Health, Inc. (Nasdaq – OPCH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)

October 6 at 10:25 AM | globenewswire.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Rated “Hold” by Wall Street Analysts

October 1, 2026 | defenseworld.netD

Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Has Consensus Target Price of $108.11 According to Analysts

October 1, 2026 | americanbankingnews.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Rated "Hold" by Wall Street Analysts

October 1, 2026 | marketbeat.com

Lantheus Holdings, Inc. Receives Cms Transitional Pass-Through Status and Permanent Hcpcs Code for Pylarify Truvu

September 30, 2026 | marketscreener.comM

Lantheus Holdings, Inc. erhält CMS-Status für vorübergehende separate Erstattung und dauerhaften HCPCS-Code für Pylarify TruVu

September 30, 2026 | de.marketscreener.comD

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

September 30, 2026 | globenewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SoundThinking, Inc. (Nasdaq – SSTI), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)

September 29, 2026 | globenewswire.com

Lantheus Holdings, Inc. Announces First Patient Dosed In SPARROW Phase 2/3 Registrational Trial Evaluating LNTH-2401 In Prostate Cancer

September 28, 2026 | marketscreener.comM

Lantheus Holdings, Inc.: Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

September 28, 2026 | finanznachrichten.de

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

September 28, 2026 | globenewswire.com

Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval

September 26, 2026 | finance.yahoo.com

Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval

September 25, 2026 | finance.yahoo.com

Lantheus (NASDAQ:LNTH) Stock Price Breaks Below Fifty Day Moving Average - Here's What Happened

September 25, 2026 | marketbeat.com

FDA approval for Lantheus’ Bravnetsa

September 24, 2026 | thepharmaletter.comT

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

September 24, 2026 | globenewswire.com

3 Reasons LNTH is Risky and 1 Stock to Buy Instead

September 23, 2026 | finance.yahoo.com

Lantheus Holdings, Inc. Receives Final FDA Approval for BRAVNETSA for Treatment of GEP-NETs

September 22, 2026 | marketscreener.comM

FDA approves Lantheus' Bravnetsa as equivalent to Lutathera for GEP-NETs

September 22, 2026 | streetinsider.com

Lantheus Holdings stock faces a new Curium review window

September 22, 2026 | ad-hoc-news.deA

FDA Approves Lantheus' Bravnetsa As Equivalent To Lutathera For Neuroendocrine Tumors

September 22, 2026 | rttnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, LNTH, AMRX, and BLTE Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$20.30 -0.05 (-0.25%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$20.33 +0.03 (+0.14%)

As of 07:26 AM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Belite Bio NASDAQ:BLTE

$155.61 -3.57 (-2.24%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$155.78 +0.17 (+0.11%)

As of 07:26 AM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Compass Pathways NASDAQ:CMPS

$11.56 -0.04 (-0.34%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$11.60 +0.04 (+0.35%)

As of 07:27 AM Eastern

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Lantheus NASDAQ:LNTH

$99.95 -0.24 (-0.24%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$100.00 +0.05 (+0.05%)

As of 07:14 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPS, LNTH, AMRX, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPS, LNTH, AMRX, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPS, LNTH, AMRX, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, LNTH, AMRX, and BLTE Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Belite Bio NASDAQ:BLTE

Compass Pathways NASDAQ:CMPS

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPS, LNTH, AMRX, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPS, LNTH, AMRX, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPS, LNTH, AMRX, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, LNTH, AMRX, and BLTE Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Belite Bio NASDAQ:BLTE

Compass Pathways NASDAQ:CMPS

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools